KRAS and colorectal carcinoma: Targeting Hippo signaling in combination with the KRAS inhibitor showed an increased efficacy of the inhibitor on “undruggable” KRAS-inhibitor-resistant CRC, suggesting the involvement of Hippo signaling in chemoresistance [59].